Iwilfin (Eflornithine HCl) Patent Expiration, LOE Window & CMS Spending

Iwilfin (Eflornithine HCl) by Uswm: FDA Orange Book LOE 2036-02-12, 0 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and $9,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUswm
FDA Application & PathwayN215500 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-02-12
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$5.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,000 intro WAC)